The effect of N1-dansylspermine, a polyamine analogue and competitive polyamine antagonist, and Ro25,6981, a noncompetitive polyamine antagonist with good affinity and selectivity for the GluN2B subunit, on locomotor activity in naive mice was investigated. Furthermore, the ability of the polyamine antagonists to reverse reserpine-induced hypokinesia was assessed, 24 h after injection of a catecholamine-depleting dose of reserpine (5 mg/kg, subcutaneous), to investigate the therapeutic potential of polyamine antagonists in Parkinson's disease. N1-dansylspermine significantly decreased locomotor activity in naive animals (P < 0.001) but caused a mild, but significant increase in locomotor activity in reserpinized mice at the highest dose tested (P < 0.05). Ro25,6981 significantly stimulated locomotor activity in naive animals (P < 0.001) and had a slight significant stimulatory effect on reserpine-induced hypokinesia (P = 0.05). N1-dansylspermine and Ro25,6981 had opposite effects on locomotor activity in naive mice, but both had a mild antiparkinsonian effect in the reserpine model. These findings suggest that antagonism of the polyamine binding site on the GluN2B subunit can reduce hypokinesia, albeit to a limited extent.
Introduction
Parkinson's disease is a progressive movement disorder associated with neurodegeneration in the basal ganglia. It is characterized by difficulty in initiating motor activity, postural instability and a resting tremor. A classical hallmark of Parkinson's disease is the loss of dopaminergic neurons in the substantia nigra pars compacta causing dopamine denervation of the striatum [1]. This degeneration is associated with a second hallmark of the disease, the deposition of misfolded and ubiquitinated α-synuclein-containing Lewy bodies and Lewy neurites within neurons [2] . Another common feature accompanying the degeneration of dopamine neurons in Parkinson's disease is the overactivity of the glutamatergic system in the subthalamic nucleus and corpus striatum of the basal ganglia [3] . Surgical inactivation of glutamatergic neurons in the subthalamic nucleus or their efferents in the internal segment of the globus pallidus have reversed Parkinson-like symptoms in animal models [4] . Amantadine, a drug used clinically to reduce the symptoms of Parkinsonism, increases dopamine release and also may act as a weak N-methyl-D-aspartate (NMDA) receptor antagonist [5, 6] . The noncompetitive polyamine and NMDA receptor (GluN2B) antagonist ifenprodil displayed antiparkinsonian activity in the reserpine-treated rat and MPTP-lesioned marmoset models with a far better side effect profile than the competitive or channel blocking NMDA receptor antagonists [7, 8] .
Polyamines are a group of naturally occurring amines including spermine and spermidine that positively modulate the activity of NMDA receptors [9] , specifically through a binding site on the GluN1, GluN2A and, in particular, GluN2B subunits [10] . Interestingly, the physiological concentrations of the polyamines have been shown to accelerate the aggregation of α-synuclein in vitro [11] . Spermine and spermidine levels are raised in red blood cells of patients with Parkinson's disease [12] . Reserpineinduced monoamine depletion in rodents allows the rapid assessment of the antiakinetic potential of drugs, and was previously shown to detect the antiparkinsonian potential of ifenprodil [7] but the limited effect of its sister drug eliprodil [13] . The aim of this study was to assess the effect of N1-dansylspermine, a polyamine analogue and competitive polyamine antagonist [14, 15] , and Ro25,6981, a noncompetitive polyamine antagonist with good affinity and selectivity for the GluN2B subunit [16] , on locomotor activity in naive mice and in the reserpinized mouse model of Parkinson's disease to investigate the therapeutic potential of polyamine antagonists in Parkinson's disease.
Materials and methods
Male albino TO mice (20-40 g) were obtained from Tuck and Sons Ltd, Essex, UK, and were housed in groups of six under a 12 h light/dark cycle (on, 07:00-19:00 h) at an ambient temperature of 21 1°C, with food and water ad libitum. All experiments were conducted according to the requirements of Cruelty To Animals Act, 1876, European Community Directive, 86/609/EC.
Drugs and protocol
Very little is known of the pharmacodynamics and kinetics of N1-dansylspermine and Ro25,6981. An initial observation window of 2 h was chosen to give an indication of the behavioural effects of these drugs. As it was observed that locomotor effects developed rapidly in naive mice, the same duration of observation was chosen to assess the antidyskinetic effect of the drugs at a range of doses. Reserpine (5 mg/kg, subcutaneous) (Sigma-Aldrich, Dorset, UK) was dissolved in the minimum quantity of glacial acetic acid in 2/3 drops of boiled distilled water, and subsequently adjusted to volume with distilled water. Following reserpine or vehicle injection, the mice were kept at an ambient temperature of 28°C to prevent hypothermia (which occurs in response to reserpine). The polyamine antagonists were administered 24 h following reserpine or vehicle treatment. All drug treatments in the N1-dansylspermine dose-response study and the Ro25,6981 dose-response study were administered the same batch of reserpine as the relevant reserpine control. Immediately after antagonist administration, the animals were placed individually into a PanLab Actisystem (Barcelona, Spain) chamber and locomotor count was recorded in 10 min time-bins every 10 min for 2 h. N1-dansylspermine (2-20 µg, intracerebroventricular; gift of Professor Graham Shaw, Trinity College, Dublin) was dissolved in distilled water. The mice were briefly anaesthetized with 5% isoflurane (Rhone Merieux Inc., UK Lyon, France) before intracerebroventricular injection in a dose volume of 5 µl into the left cerebral ventricle using the method of Brittain [17] . Animals administered vehicle by the intracerebroventricular route began to recover within 15 s of injection, moving freely around the locomotor chamber, showing no overt signs of unusual behaviour. Ro25,6981 (1-40 mg/kg; La Roche Pharmaceuticals, Basel, Switzerland) was dissolved in distilled water and administered intraperitoneally in a volume of 5 ml/kg.
Data analysis
Results are expressed as mean SEM locomotor activity over time for each treatment. Two-way analysis of variance, with Bonferroni post-hoc analysis, was performed.
Results

Effects in naive mice
A significant main effect of N1-dansylspermine on locomotor count was observed [F(4,300) = 25.73, P < 0.001], with post-hoc analysis demonstrating a significant reduction in locomotor count at all doses in comparison with control ( Fig. 1a and b ). This was particularly apparent with the highest dose in the first 90 min of observation ( Fig. 1a and b) . A significant effect of time was also observed [F(11,300) = 35.58; P < 0.001]. The intracerebroventricular injection procedure briefly reduced locomotor activity in all groups. Following recovery, the high locomotor activity reduced over time ( Fig. 1a ). Treatment did not have the same effect at all times, as there was a significant time × treatment interaction observed [F(44,300) = 2.86; P < 0.001].
A significant main effect of Ro25,6981 on locomotor activity in naive mice was also found [F(5,360) = 109.96, P < 0.001], reflecting the significant stimulatory effect on locomotor count evident at each concentration ( Fig. 2a  and b ). No abnormalities in movement were observed, only increased exploratory behaviour that was maintained for the duration of the observation period. There was a significant effect of time [F(11, 360) = 22.67; P < 0.001], and treatment did not have the same effect at all times, as there was a significant time × treatment interaction observed [F(55,360) = 4.01; P < 0.001].
Effects in the reserpinized mouse model
The reserpine-treated animals exhibited hypokinesia, tremor and hunched posture 24 h after reserpine administration. A control group administered reserpine vehicle 24 h before the study showed no abnormalities in locomotor activity. The reserpine used in the N1-dansylspermine and Ro25,6981 studies was from different batches of the drug, and produced some variability in the extent of dyskinesia produced. Nonetheless, very clear dyskinesia was produced in both dose-response experiments, and all drug treatments were administered the same batch of reserpine as the relevant reserpine control to enable assessment of the antidyskinesia effect.
A mild, but significant, stimulatory effect of N1-dansylspermine on locomotor activity in reserpinized animals was observed [F(4,300) = 2.96, P < 0.05] (Fig. 1c ). Post-hoc analysis showed a significantly higher locomotor count with the 20 μg dose in comparison with control ( Fig. 1d ; P < 0.05). There was a significant effect of time [F(11,300) = 11.8, P < 0.001], and no time × treatment interaction was found [F(44,300) = 1.04, NS].
Ro25,6981 had a mild, stimulatory effect on locomotor activity in reserpinized animals [F(5,360) = 2.28, P = 0.05], but post-hoc analysis did not identify a significant effect of any dose in comparison with control ( Fig. 2c  and d ). There was a significant effect of time [F(11,360) = 9.32, P < 0.001], and no time × treatment interaction was found [F(55,360) = 0.75, NS].
Discussion
Amantadine, a weak NMDA receptor antagonist, is used clinically to treat the symptoms of Parkinson's disease. Its sister compound, memantine, has been studied in clinical trials for Parkinson's disease with limited success [18] , particularly in the treatment of dementia in Parkinson's disease [19] . The polyamines are positive modulators of NMDA receptor function in vivo [20] , and, as such, antagonists of polyamine binding sites may have therapeutic potential as motor stimulants, possibly without many of the disabling side effects of the more direct competitive and open channel antagonists of the NMDA receptor [21] . Ifenprodil has been shown to have antiparkinsonian actions in reserpinized rat, 6-hydroxydopamine-lesioned primate and MPTP-lesioned primate models [7, 8, 22] . This antiparkinsonian action is thought to occur through inhibition of overactive NR2Bcontaining NMDA receptors [7] . However, it is also known that ifenprodil and its sister compound eliprodil possess a degree of calcium and sodium channel antagonist potential [23, 24] , inhibit inwardly rectifying potassium channels [25] and can also block the NMDA receptor-evoked release of neuromodulators in the striatum [26] . There is also evidence that eliprodil suppresses the uptake and enhances the efflux of dopamine in striatal tissues [27] . In addition, ifenprodil-like GluN2B antagonists have a high degree of interaction with α1-adrenergic receptors, which have been suggested to contribute to the adverse side effects of these compounds [28] . The extent to which the interactions with GluN2B subunits or sites other than GluN2B subunits contribute to the overall effect of ifenprodil-like GluN2B antagonists in-vivo is, as yet, unclear.
The ifenprodil-like analogue used in this study, Ro25,6981, has a very high affinity for GluN2B subunits [16] . Ro25,6981 (at a dose of 10 mg/kg intraperitoneally) has recently been shown to be as effective at inhibiting conditioned fear as MK801, however without the attendant hyperlocomotion, ataxia and stereotypy associated with MK801 [29] . In the present study, we investigated significantly higher doses in mice (≤ 40 mg/kg) and observed hyperlocomotion that was maintained for the duration of the observation period, suggesting a duration of effect of Ro25,6981 of greater than 2 h. It is also notable that no other motor abnormalities were observed with even the highest dose (40 mg/kg). Ro25,6981 had a slight significant stimulatory effect on reserpine-induced hypokinesia, suggesting a mild antiparkinsonian effect. This finding is in line with a recent study that showed that Ro25,6981 enhanced the antiakinetic effect of L-DOPA in rats with 6-hydroxydopamine lesions [30] . N1-dansylspermine is a potent polyamine competitive antagonist acting via the positive polyamine modulatory binding site on the NMDA receptor [31] . In naive mice, N1-dansylspermine caused reduced locomotor activity. Sedation has previously been reported following intracerebroventricular administration of 1,10-diaminodecane and diethylenetriamine, two polyamine analogues with some antagonist activity [32] . In this study, N1-dansylspermine had a mild, but significant stimulatory effect in reserpinized mice, indicating that an interaction with the polyamine binding site on the GluN2B subunit can reduce hypokinesia, albeit mildly.
Conclusion
The GluN2B antagonist, Ro25,6981, and the competitive polyamine antagonist, N1-dansylspermine, both mildly reduced hypokinesia in the reserpinized mouse model of Parkinson's disease. These findings suggest that antagonism of the polyamine binding site on the GluN2B subunit can reduce hypokinesia, albeit only to a limited extent. It may be worthwhile to assess the effect of repeated administration of polyamine antagonists in a more dopamine-specific neurotoxic or genetic model of Parkinson's disease, but it may be that their therapeutic potential in Parkinson's disease is limited. 
